Sai Life Sciences has announced a strategic partnership with Mabtech to strengthen immunology research capabilities and expand service offerings in the biotechnology sector. This collaboration marks a significant step in enhancing the company's research infrastructure and global presence.

Strategic Partnership Details

The partnership between Sai Life Sciences and Mabtech focuses on boosting immunology research through combined expertise and resources. The collaboration aims to leverage both companies' strengths to deliver enhanced research capabilities and advanced scientific solutions.

Boston Laboratory Establishment

As part of this strategic initiative, Sai Life Sciences has opened a new laboratory facility in Boston, which will serve as the US hub for the Eyra platform. This expansion represents the company's commitment to strengthening its presence in the American market and providing localized services to clients.

Enhanced Service Capabilities

The partnership will enable both companies to jointly provide advanced immunology assay services. This collaboration combines Sai Life Sciences' research capabilities with Mabtech's specialized expertise, creating a comprehensive service offering for clients in the immunology research sector.

The establishment of the Boston facility and the strategic partnership with Mabtech demonstrates Sai Life Sciences' focus on expanding its global footprint and enhancing its research and development capabilities in specialized areas of biotechnology.

Sai Life Sciences Limited has announced its earnings conference call to discuss the third quarter financial results for FY26, scheduled for February 6, 2026. The pharmaceutical contract research and manufacturing organization informed stock exchanges about this investor meeting pursuant to regulatory requirements.

Conference Call Details

The earnings conference call will be held on Friday, February 6, 2026, at 4:00 PM IST, with a duration of one hour until 5:00 PM. The session will focus on discussing the company's unaudited financial results for the third quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature key senior management representatives who will lead the discussion on quarterly performance:

• Krishna Kanumuri - Managing Director & Chief Executive Officer
• Siva Chittor - Director and Chief Financial Officer

The call will begin with a brief management discussion on earnings performance, followed by an interactive Question & Answer session with analysts and institutional investors.

Access Information

Participants can join the conference call through multiple channels. The company has provided domestic dial-in numbers along with international toll-free options for global participants. International attendees can use toll-free numbers for USA (18667462133), UK (08081011573), Singapore (8001012045), and Hong Kong (800964448).

A pre-registration facility is available for participants who wish to dial in directly without waiting for operator assistance. The company has provided a specific registration link for this convenience feature.

Regulatory Compliance

The announcement was made on January 28, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Runa Karan signed the regulatory filing, ensuring proper disclosure to both BSE Limited (Scrip Code: 544306) and National Stock Exchange of India Limited (Scrip Symbol: SAILIFE).

Sai Life Sciences operates as a global Contract Research, Development, and Manufacturing Organization (CRDMO), partnering with pharmaceutical and biotech companies for drug discovery, development, and commercialization services. The company is headquartered in Hyderabad with integrated solutions spanning medicinal chemistry, process development, and clinical manufacturing.